| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PIKFYVE |
| Uniprot No | Q9Y2I7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1493-2098aa |
| 氨基酸序列 | KKQSLCEVLQAWNNRLQDLFQQEKGRKRPSVPPSPGRLRQGEESKISAMD ASPRNISPGLQNGEKEDRFLTTLSSQSSTSSTHLQLPTPPEVMSEQSVGG PPELDTASSSEDVFDGHLLGSTDSQVKEKSTMKAIFANLLPGNSYNPIPF PFDPDKHYLMYEHERVPIAVCEKEPSSIIAFALSCKEYRNALEELSKATQ WNSAEEGLPTNSTSDSRPKSSSPIRLPEMSGGQTNRTTETEPQPTKKASG MLSFFRGTAGKSPDLSSQKRETLRGADSAYYQVGQTGKEGTENQGVEPQD EVDGGDTQKKQLINPHVELQFSDANAKFYCRLYYAGEFHKMREVILDSSE EDFIRSLSHSSPWQARGGKSGAAFYATEDDRFILKQMPRLEVQSFLDFAP HYFNYITNAVQQKRPTALAKILGVYRIGYKNSQNNTEKKLDLLVMENLFY GRKMAQVFDLKGSLRNRNVKTDTGKESCDVVLLDENLLKMVRDNPLYIRS HSKAVLRTSIHSDSHFLSSHLIIDYSLLVGRDDTSNELVVGIIDYIRTFT WDKKLEMVVKSTGILGGQGKMPTVVSPELYRTRFCEAMDKYFLMVPDHWT GLGLNC |
| 预测分子量 | 93 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PIKFYVE重组蛋白的参考文献及其摘要概括：
1. **文献名称**: *"PIKfyve Regulation of Endosome-Linked Pathways"*
**作者**: Ferguson SM, et al.
**摘要**: 探讨了重组PIKFYVE蛋白在调控内体成熟和溶酶体功能中的作用，通过体外实验证明其磷酸化活性对细胞内囊泡运输和自噬过程的关键影响。
2. **文献名称**: *"Structural Insights into PIKFYVE Kinase Using Recombinant Protein Expression"*
**作者**: Jefferies HBJ, et al.
**摘要**: 利用重组PIKFYVE蛋白解析其激酶结构域的三维构象，揭示了与底物结合的分子机制，为开发靶向PIKFYVE的小分子抑制剂提供结构基础。
3. **文献名称**: *"Recombinant PIKFYVE in Disease Models: Implications for Therapeutic Targeting"*
**作者**: Bach AC, et al.
**摘要**: 研究重组PIKFYVE蛋白在神经退行性疾病模型中的功能异常，证明其活性失调可导致溶酶体贮积症，并验证了通过药物调控重组蛋白活性改善病理表型的潜力。
(注：以上文献为示例，实际引用需根据具体论文调整。)
PIKFYVE, a phosphoinositide kinase encoded by the *PIKFYVE* gene in humans, is a dual-function enzyme with both phosphatidylinositol-5-phosphate (PtdIns5P) 4-kinase and phosphatidylinositol-3-phosphate (PtdIns3P) 5-kinase activities. It catalyzes the phosphorylation of PtdIns5P to generate phosphatidylinositol-4.5-bisphosphate (PtdIns(4.5)P₂) and converts PtdIns3P to phosphatidylinositol-3.5-bisphosphate (PtdIns(3.5)P₂), two critical signaling lipids regulating membrane trafficking, endosomal maturation, lysosomal homeostasis, and autophagy. Structurally, PIKFYVE contains an N-terminal FYVE domain for membrane targeting, a chaperonin-like domain, and a C-terminal catalytic kinase domain. Dysregulation of PIKFYVE is linked to pathologies, including cancer, neurodegenerative disorders, and infectious diseases, due to its role in vesicle transport, ion channel regulation, and cellular stress responses.
Recombinant PIKFYVE protein, produced via heterologous expression systems (e.g., insect or mammalian cells), retains enzymatic activity and is widely used to study its biochemical functions, screen inhibitors, and dissect signaling pathways. Its applications extend to investigating PIKFYVE’s interaction with regulatory proteins, such as VAC14 and FIG4. which form a ternary complex essential for lipid kinase activity. Inhibitors targeting PIKFYVE, such as apilimod, are under exploration for anticancer and antiviral therapies, leveraging its role in blocking endosomal escape of pathogens (e.g., Ebola, SARS-CoV-2) or inducing cancer cell death via lysosomal dysfunction. Recombinant PIKFYVE also aids in structural studies to resolve mechanisms of lipid substrate recognition and inhibitor binding. Overall, this protein serves as a vital tool for understanding phosphoinositide metabolism and developing therapeutics for diseases linked to PIKFYVE dysregulation.
×
